Verici Dx PLC CAP accreditation

TIDMVRCI

Verici Dx PLC

08 January 2024

Verici Dx plc

("Verici Dx" or the "Company")

Verici Dx Clinical Laboratory achieves CAP accreditation

Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its testing laboratory in Franklin, TN, has been accredited by the internationally recognised College of American Pathology (CAP) following the completion of an on-site audit. The Company, whose clinical laboratory is already CLIA certified, voluntarily sought the accreditation as part of its on-going commitment to maintaining best in class quality systems.

CAP accreditation is a hallmark of quality and excellence in clinical laboratory services and adds to the Company's existing portfolio of quality assurance awards and recognition.

In achieving the CAP accreditation requirements, which often exceed the standards from CLIA, FDA and OSHA, Verici Dx exhibits focus on excellence in patient care and laboratory safety. It also further demonstrates the laboratory's ability to deliver reliable and accurate test results to support patient clinical management.

Patti Connolly, Chief Operating Officer at Verici Dx, said: " We are pleased that our highly skilled laboratory team successfully achieved this accreditation with no deficiencies, findings, or recommendations identified during the audit. This accomplishment affirms our commitment to operating at the highest standards that healthcare providers, patients, and regulatory bodies expect."

Enquiries:

 
Verici Dx                                                        www.v ericidx .com 
Sara Barrington, CEO                                                Via Walbrook PR 
Julian Baines, Chairman 
 
Singer Capital Markets (Nominated                                Tel: 020 7496 3000 
 Adviser & Broker) 
Aubrey Powell / Sam Butcher / Jalini 
 Kalaravy 
 
Walbrook PR Limited                   Tel: 020 7933 8780 or vericidx@walbrookpr.com 
Stephanie Cuthbert / Sam Allen                   Mob: 07796 794 663 / 07502 558 258 
 
   About Verici Dx plc   www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABRMBTMTIMTTI

(END) Dow Jones Newswires

January 08, 2024 02:00 ET (07:00 GMT)

Verici Dx (LSE:VRCI)
Historical Stock Chart
From May 2024 to Jun 2024